Current Hypertension Reports最新文献_第2页

MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice. MASLD和心血管风险：临床实践的机制和意义。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-08-01 DOI: 10.1007/s11906-026-01380-9

Sainan Li, Michel Toutoungy, Janvi Patel, Indira Bhavsar-Burke, Lisa B VanWagner

{"title":"MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice.","authors":"Sainan Li, Michel Toutoungy, Janvi Patel, Indira Bhavsar-Burke, Lisa B VanWagner","doi":"10.1007/s11906-026-01380-9","DOIUrl":"10.1007/s11906-026-01380-9","url":null,"abstract":"Purpose of review: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic cardiometabolic disease. This review summarizes recent advances in epidemiology, pathophysiology, biomarkers, and treatment relevant to cardiovascular risk assessment and management.Recent findings: Fibrosis stage is the strongest independent predictor of cardiovascular outcomes in MASLD, conferring up to a 2.5-fold increase in events beyond traditional risk factors. Noninvasive tools, including Fibrosis-4 (FIB-4) and liver stiffness measurement, also predict cardiovascular mortality. Semaglutide and resmetirom offer dual hepatic and cardiometabolic benefits. MASLD affects 38% of adults globally, and cardiovascular disease (CVD) is the leading cause of death across disease stages. Fibrosis-based risk stratification remains absent from standard cardiovascular risk models despite its prognostic value. Therapies with combined liver and cardiovascular benefits are promising, but whether improving liver disease reduces cardiovascular events remains uncertain.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13428797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148653130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COMMENTARY on "Factors Associated with Preeclampsia and the Hypertensive Disorders of Pregnancy Amongst Indigenous Women of Canada, Australia, New Zealand and the United States: A Systematic Review and Meta-analysis" by Stephens et al. (2025) Published in Current Hypertension Reports. Stephens等人（2025）发表在《当前高血压报告》上的评论“加拿大、澳大利亚、新西兰和美国土著妇女中与子痫前期和妊娠高血压疾病相关的因素：一项系统回顾和荟萃分析”。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-07-30 DOI: 10.1007/s11906-026-01382-7

Guido Grassi, Rita Facchetti, Costas Thomopoulos

引用次数: 0

Toward Precision Aspirin Prophylaxis: Optimal Aspirin Dosing For Prevention of Preeclampsia. 精确阿司匹林预防：预防子痫前期的最佳阿司匹林剂量。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-07-21 DOI: 10.1007/s11906-026-01381-8

Priyanka Gaur, Rachel Friedlander, Line Malha, Amrin Khander

{"title":"Toward Precision Aspirin Prophylaxis: Optimal Aspirin Dosing For Prevention of Preeclampsia.","authors":"Priyanka Gaur, Rachel Friedlander, Line Malha, Amrin Khander","doi":"10.1007/s11906-026-01381-8","DOIUrl":"10.1007/s11906-026-01381-8","url":null,"abstract":"Purpose of review: To review contemporary evidence regarding optimal aspirin dosing for prevention of preeclampsia, focusing on dose-response relationships, timing of initiation, and phenotype-specific prophylaxis.Recent findings: Recent trials and meta-analyses have produced conflicting findings regarding whether higher-dose aspirin (100-162 mg daily) provides greater protection against preeclampsia than conventional 75-81 mg regimens. Benefit appears greatest in placental-risk phenotypes and select high-risk populations, including patients with obesity, multifetal gestation, chronic hypertension, diabetes, and multiple concurrent risk factors. Pharmacokinetic studies indicate altered aspirin metabolism and reduced platelet inhibition during pregnancy, supporting biologic plausibility for higher-dose strategies. However, pragmatic real-world studies remain mixed, and definitive recommendations are lacking. Aspirin efficacy is phenotype-dependent, and optimal dosing likely varies according to placental biology, pharmacokinetics, and baseline risk. Emerging evidence supports individualized prophylaxis emphasizing early initiation and consideration of higher-dose aspirin in select high-risk populations.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148535501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neural Control of Tissue Perfusion: Emerging Evidence and Beyond. 组织灌注的神经控制：新证据和超越。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-06-30 DOI: 10.1007/s11906-026-01378-3

Eduardo Colombari, Gustavo Rodrigues Pedrino, Pedro Lourenço Katayama, Daniel Breseghello Zoccal, Michelle Mendanha Mendonça, Debora Simões Almeida Colombari, Carlos Henrique Xavier

{"title":"Neural Control of Tissue Perfusion: Emerging Evidence and Beyond.","authors":"Eduardo Colombari, Gustavo Rodrigues Pedrino, Pedro Lourenço Katayama, Daniel Breseghello Zoccal, Michelle Mendanha Mendonça, Debora Simões Almeida Colombari, Carlos Henrique Xavier","doi":"10.1007/s11906-026-01378-3","DOIUrl":"10.1007/s11906-026-01378-3","url":null,"abstract":"Purpose of review: Tissue perfusion is tightly regulated by central neural circuits that integrate autonomic and sensory inputs to match blood flow to tissue metabolic demand. This review synthesizes current knowledge on the central mechanisms governing tissue perfusion in both physiological and pathological states, with emphasis on the organization of brain networks involved in cardiovascular control.Recent findings: Recent advances reveal that tissue perfusion is modulated not only by classical reflex pathways, but also by humoral, metabolic, immune, and neuromodulatory systems. Key brain regions, particularly within the brainstem, coordinate sympathetic and parasympathetic outflows through complex and state-dependent interactions that dynamically regulate vasomotion and cardiac function. Emerging evidence also demonstrates that maladaptive remodeling of these central networks contributes to vascular dysfunction in disorders such as hypertension and heart failure, promoting tissue hypoxia and end-organ damage. Central neural mechanisms play a pivotal role in the regulation of tissue perfusion under both healthy and diseased conditions. A comprehensive understanding of the neural circuits and signaling pathways involved in perfusion control may support the development of targeted therapeutic strategies aimed at restoring vascular homeostasis and improving outcomes in cardiocirculatory and neurovascular diseases.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy? 修正：肠促胰岛素激动剂类药物是否应被考虑用于一线降压治疗？

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-06-29 DOI: 10.1007/s11906-026-01377-4

Dominik Kylies, Leonie Dreher, Ulrich O Wenzel

引用次数: 0

Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease. 儿童高血压与心血管肾代谢性疾病的交叉。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-06-23 DOI: 10.1007/s11906-026-01375-6

Jessica O'Keeffe, Christina Kingshill, Jack Tompson, Andrew M South, Carissa M Baker-Smith

{"title":"Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease.","authors":"Jessica O'Keeffe, Christina Kingshill, Jack Tompson, Andrew M South, Carissa M Baker-Smith","doi":"10.1007/s11906-026-01375-6","DOIUrl":"10.1007/s11906-026-01375-6","url":null,"abstract":"Purpose of review: The purpose of this review is to describe the intersection between pediatric hypertension and advancing stages of cardiovascular, kidney metabolic syndrome in children and adolescents.Recent findings: Cardiovascular-kidney-metabolic syndrome is highly prevalent in the pediatric population. The onset of CKM in childhood is influenced by the presence of antenatal risk factors such as maternal hypertensive disorders of pregnancy. Advancing stages of CKM in children and adolescents are strongly influenced by food insecurity and social determinants of health that impact the risk for childhood obesity. Activation of the renin-angiotensin-aldosterone system is a key mediator in the relationship between antenatal risk, early life course exposure and hypertension in children and adolescents. Effective strategies for slowing the rate of advancement of CKM staging in children and adolescents require attention to early course factors that influence the development of hypertension and obesity. Likewise, management strategies and therapeutic interventions that address these factors are critical to mitigating CKM stage advancement. Although hypertension is a component of the CKM framework, the presence of hypertension in children and adolescents drives higher CKM staging. Together, hypertension and higher CKM staging are associated with increased atherosclerotic cardiovascular disease risk. Social factors, including access to healthy foods and attention to early life course nutrition are critical strategies to improving CKM and hypertension related outcomes in children and adolescents.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure? 联合醛固酮合成酶和SGLT2抑制：成功治疗血压不受控制的CKD的秘诀？

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-06-12 DOI: 10.1007/s11906-026-01376-5

Jacob M Dunn, Stephen R Sammons, Kausik Umanath, Jamie P Dwyer

{"title":"Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?","authors":"Jacob M Dunn, Stephen R Sammons, Kausik Umanath, Jamie P Dwyer","doi":"10.1007/s11906-026-01376-5","DOIUrl":"10.1007/s11906-026-01376-5","url":null,"abstract":"Purpose of review: To evaluate the emerging role of aldosterone synthase inhibitors (ASIs) in combination with sodium-glucose cotransporter 2 (SGLT2) inhibitors for the management of uncontrolled hypertension in patients with chronic kidney disease (CKD), and to assess their potential cardiorenal benefits.Recent findings: SGLT2 inhibitors confer modest blood pressure reduction alongside cardiorenal protection across diverse CKD populations. ASIs such as baxdrostat and lorundrostat demonstrate clinically meaningful reductions in systolic blood pressure, with early evidence suggesting favorable effects on albuminuria. Recent trials in CKD populations demonstrate improved blood pressure control and reductions in proteinuria, while combination therapy suggests mitigation of hyperkalemia risk through SGLT2 inhibitor-induced kaliuresis. Ongoing large-scale trials are evaluating long-term renal and cardiovascular outcomes of this combination strategy. The combination of ASIs and SGLT2 inhibitors represents a mechanistically complementary approach to targeting RAAS dysregulation, volume status, and metabolic pathways. This strategy has the potential to redefine treatment paradigms for CKD-associated uncontrolled hypertension, pending evaluation of long-term outcome benefits.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148223874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leveraging the Electronic Health Record to Identify and Manage Resistant Hypertension. 利用电子健康记录识别和管理顽固性高血压。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-06-01 DOI: 10.1007/s11906-026-01371-w

Bairavi Shankar, Anat Ben-Shlomo, Susan Cheng, Joseph E Ebinger

{"title":"Leveraging the Electronic Health Record to Identify and Manage Resistant Hypertension.","authors":"Bairavi Shankar, Anat Ben-Shlomo, Susan Cheng, Joseph E Ebinger","doi":"10.1007/s11906-026-01371-w","DOIUrl":"10.1007/s11906-026-01371-w","url":null,"abstract":"Purpose of review: Resistant hypertension (RH) affects more than a tenth of adults and yet remains relatively underrecognized and undertreated. The electronic health record (EHR) now stands as a critical tool for overcoming barriers to the diagnosis and treatment of RH, specifically with respect to aiding in detection, excluding alternate diagnoses, and guiding clinical decision making. We review how the EHR has clarified the population level prevalence of RH and its impact on both quality of life and longevity.Recent findings: We examine how the EHR can be leveraged to identify relevant specific causes of elevated blood pressure such as medication non-adherence, clinical inertia, White Coat Effect, and hyperaldosteronism, among others. Additionally, we highlight the promises and potential pitfalls that warrant consideration when implementing novel EHR interventions to address clinical challenges such as RH. In particular, we discuss the importance of balancing augmented data availability with the need for streamlined data flow to clinicians, so that enhanced workflows can both maximize efficiency and improve quality of care. As the EHR continues to transform the practice of care delivery, RH represents a uniquely well-suited area for improving clinical identification and management in ways that could not be otherwise readily achieved in practice.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148143062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy? 以肠促胰岛素激动剂为基础的Brugs是否应被考虑作为一线降压治疗？

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-05-07 DOI: 10.1007/s11906-026-01374-7

Dominik Kylies, Leonie Dreher, Ulrich O Wenzel

{"title":"Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?","authors":"Dominik Kylies, Leonie Dreher, Ulrich O Wenzel","doi":"10.1007/s11906-026-01374-7","DOIUrl":"10.1007/s11906-026-01374-7","url":null,"abstract":"Purpose of review: This review evaluates the antihypertensive potential of next-generation incretin-based therapies, including GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists. It examines their effects on blood pressure reduction, underlying mechanisms, clinical benefits, and implications for future guidelines.Recent findings: Recent large-scale trials demonstrate that incretin-based therapies such as semaglutide and tirzepatide significantly reduce body weight, blood pressure, and cardiovascular outcomes. Mediation analyses indicate that weight loss explains a substantial proportion of blood pressure reduction, while direct effects on vascular function, renal sodium handling, and neurohumoral pathways also contribute. These effects are consistent across diverse populations, including individuals without overt hypertension. Incretin-based therapies represent a promising approach in hypertension management, combining metabolic and cardiovascular benefits. Despite the lack of trials with blood pressure as a primary endpoint, current evidence supports their use in selected high-risk populations and suggests an emerging role in future guideline recommendations.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13149630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Review of Clinical Trial and Meta-Analyses of BP Treatment Strategies for Patients with Orthostatic Hypotension: Blood Pressure Management in Patients with Hypertension and Orthostatic Hypotension. 直立性低血压患者血压治疗策略的临床试验和meta分析综述：高血压和直立性低血压患者的血压管理。

IF 6.3 2区医学

Current Hypertension Reports Pub Date : 2026-04-25 DOI: 10.1007/s11906-026-01368-5

Shreyas Rajesh, Grace Rae Lee, Katie Jintian Gao, Archana Verma, Stephen P Juraschek

{"title":"A Review of Clinical Trial and Meta-Analyses of BP Treatment Strategies for Patients with Orthostatic Hypotension: Blood Pressure Management in Patients with Hypertension and Orthostatic Hypotension.","authors":"Shreyas Rajesh, Grace Rae Lee, Katie Jintian Gao, Archana Verma, Stephen P Juraschek","doi":"10.1007/s11906-026-01368-5","DOIUrl":"10.1007/s11906-026-01368-5","url":null,"abstract":"PURPOSE OF REVIEW: To review clinical trial and meta-analysis data on the effects of blood pressure (BP) pharmacologic treatment for hypertension on orthostatic hypotension (OH) to identify BP goals for patients with these concomitant conditions. FINDINGS: Hypertension and OH are commonly found together. The autonomic reflex that prevents hypotension upon standing also prevents hypertension when supine. OH, a fixed difference in systolic BP (≥ 20 mmHg) or diastolic BP (≥ 10 mmHg) between supine (or seated) and standing positions, can thus be associated with adverse outcomes related to low BP (e.g., syncopal events and falls) or high BP (e.g., coronary heart disease and stroke). While all OH stems from some degree of autonomic dysfunction, the type and extent of deficit has implications on the severity and reproducibility of the OH. Treatment strategies, moreover, differ based on predominant risks as well as OH etiology, specifically: neurologic, acute, pharmacologic, or hypertensive (cardiovascular). Hypertensive (cardiovascular) OH has been viewed traditionally through the lens of hypotensive event prevention, but emerging evidence suggests that more intensive therapy may reduce OH and prevent CVD disease with minimal effects on hypotensive events. Careful medication selection, however, is essential to reduce supine or seated hypertension, improve orthostatic BP regulation, and prevent hypotensive complications of treatment in these complex patients. Mounting evidence does not consider OH a deterrent for hypertension management; however, careful phenotyping of OH etiology and patient risks are essential for more precise patient care. ","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"28 1","pages":""},"PeriodicalIF":6.3,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13273146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0